RNA binding proteins represent an emerging class of proteins with a role in cardiac dysfunction. We show that activation of the RNA binding protein Human antigen R (HuR) is increased in the failing human heart. To determine the functional role of HuR in pathological cardiac hypertrophy, we created an inducible cardiomyocyte-specific HuR deletion mouse, and showed that HuR deletion reduces left ventricular hypertrophy, dilation, and fibrosis while preserving cardiac function in a transverse aortic constriction (TAC) model of pressure-overload-induced hypertrophy. Assessment of HuR-dependent changes in global gene expression suggests that the mechanistic basis for this protection occurs through a reduction in fibrotic signaling, specifically through a reduction in transforming growth factor beta (Tgfb) expression. Finally, pharmacological inhibition of HuR at a clinically relevant time point following the initial development of pathological hypertrophy post-TAC also yielded a significant reduction in pathological progression, as marked by a reduction in hypertrophy, dilation, and fibrosis, and preserved function. In summary, this study demonstrates a functional role for HuR in the progression of pressure overload-induced cardiac hypertrophy and establishes HuR inhibition as a viable therapeutic approach for pathological cardiac hypertrophy and heart failure.
Introduction
Heart failure is an increasing health burden that results from many common underlying factors including hypertension, coronary artery disease, and myocardial infarction, and is typically preceded by the enlargement, or hypertrophy, of the cardiac muscle, an effect that is initially beneficial and helps the heart maintain cardiac output in the face of hemodynamic stress.(1) However, the development of left ventricular hypertrophy (LVH) in response to such a pathological stimulus is not sustainable, and is associated with increased cardiac fibrosis, risk of arrhythmias, and development of heart failure (HF). The current standard-of-care treatments for HF mostly aim to relieve the underlying pressure overload and/or reduce the workload on the heart through inhibition of overstimulated neurohumoral pathways (ACE inhibitors, angiotensin receptor blockers, diuretics, and beta blockers).(2, 3) However, no current therapies directly target the molecular signaling pathways in cardiac myocytes and fibroblasts that mediate LVH and fibrosis to prevent or reverse this pathological cardiac remodeling.
Human antigen R (HuR; encoded by the Elavl1 gene) is an RNA binding protein that binds to AU rich regions in the 3'-untranslated region of many different mRNAs, including many involved in inflammation, cell growth, and fibrosis, and it directly regulates the expression of target mRNA through modulation of its stability and/or translation. (4, 5) While relatively little is known about the role of HuR in the myocardium, RNA binding proteins such as HuR are becoming recognized as potentially central regulators of cardiac physiology and pathology. (6, 7) We have recently shown that HuR is both necessary and sufficient for hypertrophic growth in cultured primary rat myocytes in response to hypertrophic stimuli in vitro. (8) In this work, we show that HuR activation is increased in failing human hearts. We then use a mouse model of transverse aortic constriction (TAC) to induce LV pressure overload, a well-established model of aortic stenosis, to demonstrate that cardiac myocyte specific deletion of HuR protects against pathological remodeling and functional decline in this model. Importantly, we also utilize a novel small molecular inhibitor of HuR to show that pharmacological inhibition of HuR at a clinically relevant time point following the onset of initial pathology improves survival and significantly slows the decline of cardiac function and progression of LV remodeling. Furthermore, HuR activity in the hypertrophic heart co-localizes with regions of fibrosis, and the development of fibrosis is blunted following either HuR deletion or pharmacological inhibition. Lastly, RNA-seq analysis also suggests modulation of fibrotic signaling as a key mechanism to HuR-mediated cardiac pathology.
This work demonstrates a functional role for HuR in the development and progression of pathological LVH and heart failure. Importantly, we not only establish the benefit of HuR targeting using either inducible, tissue-specific HuR deletion or pharmacological inhibition, but we also begin to decipher the underlying mechanisms of this effect. As there are currently no pharmacological inhibitors of HuR that have been demonstrated for in vivo applications, this work is also critical in demonstrating that HuR represents a viable therapeutic target for the treatment of pathological LVH and heart failure.
Results

HuR activation is increased in human heart failure
HuR resides predominately in the nucleus in an inactive form and translocates to the cytoplasm upon activation where it exerts its post-transcriptional regulation via target mRNA binding. (4, 9) We have previously shown that HuR cytoplasmic translocation is increased in primary neonatal rat ventricular myocytes (NRVMs) following a hypertrophic stimulus. (8) To determine HuR activity in failing human myocardium, we performed HuR immunofluorescence staining on healthy donor hearts as well as explanted tissue from left ventricular assist device (LVAD) implantation. Representative images show an increase in HuR cytoplasmic translocation in failing human myocardium (LVAD) vs. healthy donor tissue ( Fig. 1 ). In addition, HuR staining also shows a similar pattern of increased HuR activation in a mouse model of transverse aortic constriction (TAC)-induced pathological left ventricular hypertrophy (LVH) ( Fig.  S1 ).
Cardiac Myocyte-specific deletion of HuR reduces development of pathological LVH
To achieve inducible cardiomyocyte-specific HuR deletion (iCM-HuR -/-), we crossed HuR-floxed mice (HuR fl/fl )(10) with mice expressing a cardiac myocyte specific inducible Cre recombinase (αMHC-mER-Cre-mER) (11) , and induced Cre recombinase activity through a daily i.p. injection of 4-hydroxy-tamoxifen (4-OHT) (60 mg/kg/day) for 5 days as previously described ( Fig. S2 ).(11) Importantly, deletion of HuR did not affect basal cardiac function (Fig. S3 ). The absence of a basal cardiac phenotype in iCM-HuR -/mice is not surprising given our data that HuR appears mostly inactive in adult myocardium under resting conditions ( Fig. 1 and S1).
To determine the role of HuR in pathological cardiac hypertrophy, iCM-HuR -/mice and tamoxifen-treated Cre + /HuR +/+ littermate controls underwent transverse aortic constriction (TAC), a model of LV pressure overload that results in a predictable and reproducible progression from compensated LVH to decompensated LVH to heart failure. Sham procedure groups were included as surgical/manipulation control groups. At eight weeks post-TAC, iCM-HuR -/hearts show a preserved cardiac architecture and reduced hypertrophy (LV weight/body weight ratio) compared to Cre + /HuR +/+ control hearts ( Fig. 2A-B ). Interestingly, while myocyte-specific deletion of HuR does not completely inhibit the development of LVH, it does appear to completely inhibit the induced expression of the hypertrophic marker genes ANF (atrial natriuretic factor; Nppa) and BNP (brain natriuretic protein; Nppb) at eight weeks following TAC ( Fig. 2C -D).
HuR deletion delays the transition from compensated to decompensated LVH
Longitudinal assessment of LV mass (normalized to body weight) via echocardiography shows a significant increase in LV mass in control mice at two weeks following aortic constriction, whereas the LV mass of iCM-HuR -/mice increases in a much more gradual manner ( Fig. 3A ) with a significant blunting in total LV mass gain from baseline compared to control at eight weeks post-TAC ( Fig. 3B ). Moreover, LV posterior wall thickness was significantly increased at two weeks post-TAC in the control mice, followed by a gradual thinning of the LV wall as expected with a progression to decompensated hypertrophy and LV dilation ( Fig. 3C ). However, much like the gradual progression of LV mass, the LV posterior wall thickness in iCM-HuR -/mice shows a gradual hypertrophy, suggesting a delayed progression of the hypertrophic response in the absence of HuR ( Fig. 3C ).
LV dilation and wall thinning are both hallmarks of the maladaptive cardiac remodeling that occurs as pathological LVH progresses to decompensation and heart failure.(12) Weekly assessment of both LV end diastolic ( Fig. 3D ) and LV end systolic ( Fig. 3E ) volume shows a significant reduction in LV dilation starting at 4 weeks post-TAC in the iCM-HuR -/mice. Accordingly, iCM-HuR -/mice display significantly less LV dilation at 8 weeks post-TAC than their littermate controls ( Fig. 3F ).
HuR deletion preserves cardiac function following LV pressure overload
The initial development of hypertrophy is thought to be a compensatory response to maintain cardiac output in the face of hemodynamic stress. Because of this, there is concern by some that inhibition of the hypertrophic process may result in a rapid loss of systolic function in pressure overload. A modest decline in cardiac function, as measured via LV ejection fraction, is observed in both control and iCM-HuR -/mice in the first few weeks following TAC ( Fig. 3G ). However, as the control mice continue to decline from 6-8 weeks post-TAC, LV ejection fraction in the iCM-HuR -/mice remains stable and significantly improved compared to control ( Fig. 3G ). At 8 weeks following TAC, total decline of LV ejection fraction was significantly less in the iCM-HuR -/mice compared to control (Fig. 3H) .
In vivo, invasive pressure catheterization was performed to confirm equal pressure gradients between control and iCM-HuR -/mice ( Fig. S4 ) and determine the rate of LV pressure changes in the two groups. Results show that iCM-HuR -/mice had a preserved rate of both LV developed pressure (+dP/dt; Fig. 3I ) and LV relaxation (-dP/dt; Fig. 3J ).
Deletion of HuR reverses genome wide changes in TAC-induced gene expression
To determine the mechanisms by which myocyte-specific HuR deletion mediates the hypertrophic response, we performed RNA sequencing to identify HuR-dependent changes in transcript expression. RNA-seq was performed on control sham, iCM-HuR -/sham, control TAC, and iCM-HuR -/-TAC hearts at 8 weeks following surgical manipulation ( Fig. 4A ; Table S1 ). Comparison of the sham groups confirms that HuR plays little role in mature, non-stressed myocytes as HuR deletion had minimal impact on basal transcript levels; only 4 of 46,989 transcripts were found to be significantly dysregulated between control and iCM-HuR -/sham groups (Table S1 ). Applying a rather stringent statistical filter of a false detection rate at 0.01 we identified 2006 distinct mRNA transcripts whose expression was significantly altered by TAC (control sham vs. control TAC; Fig. 4B ; Table S2 ). Applying the same strict statistical filter, we found that 59 of these genes are strongly regulated by HuR ( Fig. 4B ; Table S3 ).
Using a principal component analysis (PCA) plot to visualize broad level changes in TAC and HuR-dependent changes in transcript expression shows the two sham groups clustering together with a strong shift in TAC-dependent transcript changes in control mice that is reversed in HuR-deletion mice ( Fig. 4C) . A more in-depth look at the 2006 TAC-dependent transcript changes shows a recovery/reversal of TAC-induced changes in 1865 (92.9%) of these 2006 transcripts, with 1 (0.1%) being unaffected, and 140 (7.0%) being exacerbated upon HuR deletion ( Fig. 4D ). Furthermore, all 59 of the transcripts identified as being strongly HuR-dependent show a reversal or recovery of TAC-mediated changes in iCM-HuR -/mice ( Fig. 4D ; inset).
Gene ontology clustering and enrichment analysis of the 59 HuR-dependent transcripts shows that HuR predominately regulates the expression of genes involved in cell growth and development (tissue development, system development) and fibrosis/ECM remodeling (fibril organization, collagen fibril organization) ( Fig. 4E ). Given that pathological LVH is known to induce both cell growth (hypertrophy) and fibrotic signaling pathways, a reversal in the expression changes of these genes in iCM-HuR -/mice is not unexpected.
HuR mediates the development of cardiac fibrosis
In accordance with the RNA-seq data suggesting a strong role for HuR in the development of cardiac fibrosis, we also observe a significant reduction in fibrosis in the iCM-HuR -/hearts compared to control at 8 weeks post-TAC ( Fig. 5 ). RNA-seq results show a significant HuR-dependent blunting of TAC-induced expression of 16 pro-fibrotic genes (taken from the 59 identified HuR-dependent genes in Fig 4; Fig. 6A ). Furthermore, we show a robust increase in protein expression of periostin, a marker for activated myofibroblasts (13) , in the control mice that is nearly ablated in the iCM-HuR -/mice ( Fig. 6B ).
While compelling, this data alone does not allow us to conclude whether HuR deletion plays a direct role in the inhibition of fibrotic signaling in the heart, or whether the reduction in fibrosis is an indirect consequence due to the inhibition of pathological LVH. However, activation of HuR in hypertrophic myocytes at 8 weeks post-TAC colocalizes with regions of fibrosis ( Fig. 6C ), supporting a functional link between the two. We utilized isolated neonatal rat ventricular myocytes (NRVMs) to show that Tgfb mRNA expression in response to hypertrophic stimuli in cardiac myocytes is dependent on HuR ( Fig. 6D ). To demonstrate that HuR directly regulates Tgfb expression in myocytes, we performed an RNA-protein cross-linking immunoprecipitation (CLIP) to show that direct binding of HuR to the Tgfb mRNA transcript ( Fig. 6E ). Additionally, HuR appears to mediate Tgfb expression by stabilizing the transcript, as our results show that, following treatment with actinomycin D (2.5 ug/ml), HuR inhibition led to expedited degradation of Tgfb mRNA ( Fig. 6F ). Finally, a HuR-dependent role in Tgfb signaling in hypertrophy is also supported by our RNA-seq data showing a recovery of TACdependent gene expression changes for transcripts associated with positive regulation of Tgfb signaling ( Fig. 6G and Table S4 ).
Pharmacological inhibition of HuR reduces further progression of LVH and preserves cardiac function
To determine the potential feasibility of inhibiting HuR as a therapeutic approach, we used KH-3, a novel small-molecule inhibitor of HuR, to achieve in vivo inhibition following the initial onset of pathological LVH. We have previously demonstrated the inhibition of hypertrophic growth in vitro using earlier generation precursors of KH-3. (8) In this experiment, we subjected 20 mice to TAC and allowed them to progress for 4 weeks prior to randomization into two groups with indistinguishable cardiac mass and function (Fig. S5 ). These groups were then treated with either vehicle or KH-3 (60 mg/kg injected i.p. 3x weekly) for 7 additional weeks.
Mice treated with KH-3 display increased survival ( Fig. 7A ) and maintain relatively normal sized hearts ( Fig. 7B-C) . Longitudinal assessment of LV mass confirms that all animals had a significant increase in LV mass prior to initiating KH-3 treatment ( Fig. 7D ). However, LV mass in vehicle treatment mice continued to increase, whereas KH-3 inhibited further increase in LV mass, and LV mass in KH-3 animals at 11 weeks post-TAC is not significantly different than immediately prior to randomization ( Fig. 7D-E ). In addition, KH-3 treated animals had significantly less cardiac mass when normalized to either body weight or tibia length ( Fig. 7F -G) as well as a significant reduction in ANF mRNA expression ( Fig. 7H ). Treatment with KH-3 also significantly reduced further LV dilation ( Fig. 7I-J) .
KH-3 treatment was also able to significantly reduce the rate of decline in cardiac function. Echocardiography shows a significantly preserved LV ejection fraction in KH-3 treated mice compared to vehicle ( Fig. 7K-L) . KH-3 also shows a significant preservation in the rate of LV relaxation (-dP/dt) and a strong trend to preserving the rate of positive LV pressure generation (+dP/dt) ( Fig. 7M-N) . Importantly, we show via in vivo pressure catheterization that KH-3 and vehicle treated groups had similar LV pressure gradients ( Fig. S6 ) and that KH-3 treatment had no effect on peripheral blood pressure ( Fig. S7 ).
Inhibition of HuR via KH-3 reduces cardiac fibrosis
Vehicle treated hearts show a significant degree of cardiac fibrosis at 11 weeks post-TAC ( Fig. 7O , upper panel), while treatment with KH-3 significantly reduced the amount of cardiac fibrosis ( Fig. 7O , lower panel). Interestingly, the overall reduction in fibrosis appears to be most strongly attributed to a reduction in interstitial fibrosis ( Fig.  7O , right panes). Western blotting also shows a significant reduction in the protein expression of fibronectin and periostin in mice given KH-3 ( Fig. 7P ).
Discussion
Despite being highly expressed in the heart, relatively little is known about the role of HuR in the myocardium. However, there is growing interest in the functional role that HuR and other RNA binding proteins may play as central regulators of posttranscriptional gene expression in cardiac physiology and pathology.(6, 7) To assess the functional role of HuR in the development and progression of pathological cardiac hypertrophy, we created the first cardiac-specific HuR deletion mouse (iCM-HuR -/-). Characterization of these mice did not identify any basal differences in phenotype between iCM-HuR -/and control mice, and HuR deletion had minimal impact on basal (sham) gene expression. This was expected given our prior in vitro work (8), as well as results presented here, showing minimal cytoplasmic localization (activation) of HuR in non-stressed myocytes. However, following TAC, the iCM-HuR -/mice are significantly protected from pathology, as evidenced by reduced LV hypertrophy, preserved cardiac function, reduced LV chamber dilation, and lessened cardiac fibrosis.
It is interesting to note that some degree of compensated LV hypertrophy still occurs in the iCM-HuR -/mice. These results demonstrate that myocyte-specific deletion of HuR only partially blunts or slows the development of hypertrophy, but more strongly reduces the pathological LV remodeling and fibrosis associated with progression to a decompensated phase and functional decline. It has been shown that load-induced compensated LV hypertrophy is not a strict requirement to maintain contractile performance in a mouse heart (14) , and it has been argued that cardiac hypertrophy in response to pathological stimuli is not in fact a beneficial compensatory response. (15) Thus, the protection observed from the deletion of HuR could be due to an inhibition of hypertrophic growth, or a more direct inhibition of one or more underlying mechanisms that drive the transition from a 'compensated' hypertrophy to a state of pathological hypertrophy.
Prior work has suggested that HuR plays a central role in the cardiac response to stress following ischemia/reperfusion injury (myocardial infarction). (16, 17) Krishnamurthy, et al showed that HuR expression increases following ischemic injury and plays a role in mediating post-infarct remodeling and Tgfb expression. However, it was unclear from this work in which cell types HuR plays a central role, and the authors postulated a key role for HuR expression in infiltrating leukocytes. While HuR is certainly highly expressed in these cells, it is also expressed in many resident cell types within the myocardium, and our results are the first to demonstrate a clear role for HuR signaling specifically in myocytes. In this work, we show that HuR activation is increased in the myocytes of hypertrophic hearts, and the mechanistic basis of the protection observed in iCM-HuR -/mice following TAC is potentially through an inhibition of Tgfb expression and subsequent development of cardiac fibrosis. This repressed level of Tgfb expression is confirmed in our RNA-seq studies, where additional positive regulators of this pathway are reduced and suppressive genes show little to no changes.
TGFB is produced and secreted by myocytes in response to hypertrophic stimuli, and can initiate myofibroblast activation (and subsequent cardiac fibrosis) in a paracrine fashion. (18) (19) (20) TGFB is increased in hypertrophic myocardium and is a primary initiator of myofibroblast activation and fibrotic signaling, which is a critical step that leads to extracellular matrix (ECM) remodeling and cardiac fibrosis. (18, 19) However, the mechanistic details of how TGFB expression is regulated in hypertrophic cardiomyocytes remain unclear. HuR has been shown to mediate TGFB expression and pro-fibrotic functions in fibroblasts as well as macrophages (17, 21) , and our data shows for the first time that HuR may play a similar role in the myocytes, as HuR knockdown dramatically reduced NRVM expression of TGFB in response to phenylephrine. Our data also shows that Tgfb is a directly bound target of HuR and that HuR stabilizes Tgfb mRNA. Moreover, a central role for HuR in controlling myocyte-mediated paracrine activation of fibrotic signaling would explain our RNA-seq results demonstrating that many of the HuR-dependent genes were identified as having pro-fibrotic roles. Interestingly, Tgfb itself was not among the genes that we found to be differentially regulated by TAC or HuR, but is supported by seminal work by Villarreal and Dillman showing that Tgfb mRNA expression was increased early (within 12 hours) following aortic banding, but returned to baseline within two weeks. (22) At least a few of the genes identified as having changed in a HuR-dependent manner are not thought to be expressed by myocytes, which would suggest an indirect or much farther upstream regulation by HuR (e.g. loss of HuR-dependent TGFB expression in myocytes and a subsequent decrease in paracrine activation of myofibroblasts). However, 50 of the 59 HuR-dependent genes are predicted to have conserved HuR binding sites, representing a significant enrichment compared to predicted transcriptome-wide HuR binding sites (Fishers Exact Test, P < 0.05; Table S5 ). On the other hand, in our data showing a colocalization of HuR activation and fibrosis, HuR appears to be activated in additional cell types than just myocytes. Thus, future work will explore the role of HuR in additional cell types in the heart as well, specifically myofibroblasts.
One of the more significant aspects of this work is that it establishes HuR inhibition as a potentially viable therapeutic approach to the clinical treatment of pathological LVH and heart failure. In demonstrating the efficacy of pharmacological targeting of HuR, we took a more clinically relevant approach of allowing the mice to progress out to four weeks post-TAC when pathological LVH could already be observed prior to randomization to drug or vehicle. We show that a chronic (7 week) treatment with a small molecule inhibitor of HuR, following the initial development of a pathological LV hypertrophy, improved survival and stunted pathological progression of LVH while eliciting no observable deleterious off-target effects to other tissues.
In summary, our results demonstrate that HuR activation in hypertrophic myocytes contributes to pathological LV remodeling in response to pressure overload. This is demonstrated through a preservation of LV function and inhibition of LV dilation following TAC in cardiac-specific HuR deletion mice. Furthermore, we show that TGFB expression and the development of cardiac fibrosis are inhibited in the absence of HuR, suggesting these pathways as a central mechanistic target of HuR activation in the myocyte. Finally, these results identify HuR as a novel therapeutic target to prevent or reduce pathological progression of left ventricular hypertrophy in response to pressure overload.
Methods
Mouse models. HuR floxed mice were described by Ghosh et al (10) and obtained from Jackson Labs (stock # 021431). To generate a cardiac-specific inducible HuR deletion model, HuR-floxed mice were crossed with mice expressing a cardiac myocyte specific inducible Cre recombinase (αMHC-mER-Cre-mER) (Jackson Labs, stock # 005657).(11) HuR deletion was achieved through a daily i.p. injection of 4hydroxy-tamoxifen (4-OHT) (60 mg/kg/day) for 5 days as previously described.(11) Mice were then allowed to recover for a minimum of 10 days following 4-OHT dosing prior to being incorporated into studies. Mice for KH-3 drug studies and RNA immunoprecipitation were wild-type C57Bl/6 mice obtained from Jackson Labs (stock # 000664). All mice were male, 10-16 weeks old at time of surgery. For tissue collection, tissues were removed and either flash frozen or fixed in 4% paraformaldehyde in PBS for further analysis.
Pharmacological HuR inhibition. HuR was pharmacologically inhibited using the small molecule KH-3, a second generation of HuR inhibitor compounds previously described by Wu et.al 2015.(23) For HuR inhibition, the KH-3 was i.p. injected 3x weekly at a dose of 60 mg/kg.
Transverse aortic constriction. Pressure overload of the LV was induced by transverse aortic constriction (TAC) surgery, as previously described. (24, 25) Briefly, animals were anesthetized under isoflurane, intubated, and ventilated. Following sternotomy, a 7-0 silk suture was used to tie down the aorta (between the innominate and left carotid arteries) around a 27-gauge needle (which was subsequently removed) to produce a constriction of uniform and reproducible diameter. Sham operated animals were subjected to the identical surgical procedures, except the suture was not tied to produce an occlusion.
In vivo hemodynamic measurements. Pressure gradients across the aortic constriction site were determined in all animals by simultaneous pressure recording in the left and right carotid arteries as previously described.(24) As a terminal procedure, mice were weighed and anesthetized using an i.p. injection of ketamine (50 μg/g) and inactin (thiobutabarbital, 100 μg/g). A 1.4-French Mikro-Tip Millar catheter pressure transducer was used to determine carotid pressure and subsequently advanced into the LV to determine dynamic pressure response and function as previously described. (26, 27) Following pressure recording, hearts were removed and atria were dissected away prior to weighing and either fixing or flash freezing for further analysis as described.
Echocardiography. All echocardiographic studies were performed as previously described. (28) Briefly, mice were anesthetized with isoflurane and body temperature was maintained at 37 o C during imaging. Using a Vevo 2100, parasternal images were obtained in short and long axes in two-dimensional mode and motion (M)-mode for quantification. These were then analyzed using VevoStrain software (Vevo 2100, v1.1.1 B1455, Visualsonic, Toronto, Canada). iCM-HuR -/mice had baseline echocardiographic measurements pre-and post-tamoxifen treatment, and all mice had measurements weekly following TAC until euthanasia.
NRVM isolation and culture. Neonatal Rat Ventricular Myocytes (NRVMs) were isolated using collagenase digestion and adhesion differential from fibroblasts. Sprague Dawley neonatal rats (1-2 days old) were decapitated and the hearts were isolated. Following removal of the atria, the ventricles were cut into small pieces and digested first in .05% trypsin/EDTA (Corning) overnight, then in collagenase II (Gibco) for 30 minutes. Cells were then spun at 100 x g followed by a 40 minute pre-plating process on non-treated plates to allow the fibroblasts to adhere. The non-adherent NRVMs were then transferred to cell culture-treated dishes in MEM alpha media (Gibco) with 10% FBS.
Histological analysis. Fixed hearts were paraffin embedded and sectioned at 6 μm thickness by the Cincinnati Children's Hospital Medical Center Department of Pathology Research Core (Cincinnati, OH, USA), and were subsequently stained with hematoxylin and eosin (H&E) and/or Masson's trichrome (MT). Immunofluorescence (IF) of HuR was performed on human and mouse failing heart samples. Samples were deparaffinized with xylene and rehydrated in serial ethanol dilutions. The samples were then heated in a sodium citrate solution (10mM Sodium citrate, 0.5% Tween20, pH=6) for 20 minutes for antigen retrieval. Triton-X 100 (0.06% solution) was used to permeabilize the samples for 30 minutes. The tissues were incubated in blocking solution (5% BSA, Sigma Aldrich) for 1 hour, followed by primary HuR antibody (Abcam ab200342) overnight, and AlexaFluor secondary antibody (Thermo Fisher Scientific A11008) for 1 hour. For DAB staining, following antigen retrieval, samples were incubated in 1% hydrogen peroxide to block endogenous peroxidase activity, followed by blocking in 5% BSA. They were then incubated overnight in primary HuR antibody RNA-seq analyses. RNA was isolated as described in Slone et al. (8) and poly(A) library and sequencing were conducted at the DNA sequencing and Genotyping Core at the Cincinnati Children's Hospital Medical Center (CCHMC). RNA was quantified with a Qubit 3.0 Flourometer (Life Technologies). Total RNA (150-300 ng) was poly(A) selected and converted to cDNA with a TruSeq Stranded mRNA Library Preparation Kit (Illumina). Different 8-base molecular barcodes were added to allow for high-level multiplexing. After 15 cycles of PCR amplification, libraries were sequences on a HiSeq 2500 sequencing system (Illumina) in Rapid Mode.
Sequenced reads were trimmed and filtered for quality with Trimmomatic as previously described. (29) Libraries were examined for quality at each step with the use of FastQC. Reads were mapped to the mouse genome (GRCm38) with the use of CLC Genomics Workbench (v. 9.5.1, Qiagen Co.). Each RNA-seq read was matched allowing 50% overlap at 95% matching to each transcript. The maximum number of mismatches allowed for each mapped read was set at 2. Gene expression was set as RPKM. Data analyses were conducted through the use of CLC Genomics with the Advanced RNA-seq plugin (1.5). Statistical tests for assessment of differential expression were conducted with a negative binominal generalized linear model with edgeR(30) with a false discovery rate of 0.01. Principal component analysis was based upon the normalized expression levels of each transcript with the use of the PCA package of R (version 3.3.2). Gene ontology of differential regulated transcripts was conducted with the use of g:Profiler.(31) Complete lists of transcripts with differential expression in relation to TAC are provided in Table S1 . RNA-seq data has been deposited to NCBI Sequence Read Archive and is available under the Bioproject PRJNA434656.
Prediction Table S2 . Blue represents recovery following HuR deletion. For (D), a two way ANOVA was performed. *P <0.05, **P <0.01 for indicated comparison. Data are shown as means ± SEM. 
